Methylene Blue: Revisited
Prashant R. Ginimuge, Jyothi S.D.

Methylene blue, an inhibitor of nitric oxide synthase and guanylate cyclase has many uses in medicine. It has been found to improve the hypotension associated with various clinical states.\(^1\) It also improves hypoxia and hyper dynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome.\(^2\) It also results in transient and reproducible improvement in blood pressure and cardiac function in septic shock.\(^3\)

**METHYLENE BLUE IN CATECHOLAMINE REFRACTORY VASOLEGIA**

Vasoplegic syndrome is generally defined as an arterial pressure <50 mm Hg, cardiac index >2.5 L /min/m\(^2\), right atrial pressure <5 mm Hg, left atrial pressure <10 mm Hg and low systemic vascular resistance <800 dyne/sec/cm\(^5\).\(^4\)

**Risk factors for vasoplegia**

Recent studies have established various risk factors for postoperative vasoplegia. These include preoperative use of heparin, ACE inhibitors, congestive heart failure, poor left ventricular function, duration of cardiopulmonary bypass (CPB), re-operation, age of the patient and opioid anesthesia.\(^5,6\)

**Mechanism of action of methylene blue in vasoplegia**

It has been suggested that refractory vasoplegia may reflect a dysregulation of nitric oxide synthesis and vascular smooth cell guanylate cyclase activation. Based on recent pathophysiologic findings it appears that the soluble intracellular enzyme guanylate cyclase is activated to produce cyclic guanosine monophosphate (C-GMP) presumably under the influence of several mediators including nitric oxide.\(^7,8\)

Methylene Blue acts by inhibiting guanylate cyclase, thus decreasing C-GMP and vascular smooth muscle relaxation.\(^9\)

**Preoperative use in cardiac surgery**

Methylene blue (1%) has been used IV over 30 min in ICU 1hour before surgery and found decreased incidence and severity of Vasoplegic syndrome in high risk patients.\(^4\)

**Intraoperative**

It has also been successfully added to CPB prime (2 mg/kg) and continued as infusion (.25- 2mg/kg/hr) during CPB to treat refractory hypotension in septic endocarditis.\(^10\)

**Postoperative**

It can also be used to treat severe vasoplegia in post operative transplant patient\(^11,13\). Hence Studies have concluded decreased mortality in vasoplegic patients after cardiac surgery with methylene blue as compared to placebo.\(^8\)

**Dosage**

Methylene blue is used as a single dose of 1.5 -2 mg /kg IV over 20 min to 1hr for rescue treatment. \(^4, 7, 8, 11, 13\)

**METHYLENE BLUE IN SEPTIC SHOCK**

A release of nitric oxide has been incriminated in the cardiovascular alterations of septic shock. Since guanylate cyclase is the target enzyme in the endothelium dependent relaxation mediated by nitric oxide, Methylene blue- a potent inhibitor of guanylate cyclase has been found very effective in improving the arterial pressure and cardiac function in septic shock.\(^3\)

Studies have found improvement in mean arterial pressure (MAP) and systemic vascular resistance (SVR) while decreasing vasopressor requirements in septic shock.\(^14\)

**METHYLENE BLUE AND HEPATOPULMONARY SYNDROME**

The hypoxemia in hepatopulmonary syndrome results from widespread pulmonary vasodilatation due to increased C-GMP. Methylene blue is found to \(\uparrow\)PaO\(_2\) and \(\downarrow\)alveolar-arterial difference for partial pressure of oxygen in all pts

---

Drs. Prashant R. Ginimuge, Assistant Professor, Department of Anaesthesiology, Belgaum Institute of Medical Sciences, Belgaum, Karnataka, Jyothi S.D., Senior Resident, Department of Paediatrics, Belgaum Institute of Medical Sciences, Dr B. R. Ambedkar Road, Civil Hospital, Belgaum- 590001, Karnataka, India.

Correspondence : Dr. Prashant R. Ginimuge, E-mail: p_gini2001@yahoo.com
with hepatopulmonary syndrome. This was due to ↓C-GMP levels by Methylene Blue-a potent inhibitor of guanylate cyclase.2

METHYLENE BLUE AS ANTIMALARIAL
Methylene Blue has already been used some 100 yr ago against malaria, but it disappeared when chloroquine (CQ) and other drugs entered the market. However recent studies has shown the efficacy of Methylene Blue as an effective and cheap antimalarial agent especially in countries with increasing resistance of P. falciparum to existing 1st line antimalarial agents-CQ and pyrimethamine-sulfadoxine.

Methylene Blue, a specific inhibitor of P. falciparum glutathione reductase has the potential to reverse CQ resistance and it prevents the polymerization of haem into haemozoin similar to 4-amino-quinoline antimalarials.

A dose of 36-72mg/kg over 3 days is the most effective schedule.15

Apart from the intrinsic antimalarial activity and CQ sensitizing action it was also considered to prevent methemoglobinemia- a serious complication of malarial anemia.16

METHYLENE BLUE IN METHEMOGLOBINEMIA
Methemoglobinemia is a life threatening condition that can be congenital or acquired. It is characterized by the inability of hemoglobin to carry oxygen because the ferrous part of the heme molecule has been oxidized to a ferric state.

Methylene Blue acts by reacting within RBC to form leukomethylene blue, which is a reducing agent of oxidized hemoglobin converting the ferric ion (Fe+++ ) back to its oxygen carrying ferrous state (Fe++ ).17

Dose commonly used is 1-2mg/kg of 1% Methylene Blue solution.17,18

METHYLENE BLUE AND CANCER
Recent research suggests that Methylene Blue and other redox cyclers induce selective cancer cell apoptosis by NAD (P) H: quinine oxidoreductase (NQO1)-dependent bioreductive generation of cellular oxidative stress. Hence Methylene Blue is being investigated for the photodynamic treatment of cancer.19

IFOSFAMIDE NEUROTOXICITY
Another, less well known use of Methylene Blue is its utility for treating ifosfamide neurotoxicity. A toxic metabolite of ifosfamide, chloroacetalddehyde, disrupts the mitochondrial respiratory chain, leading to accumulation of nicotinamide adenine dinucleotide hydrogen (NADH).

Methylene blue acts as an alternative electron acceptor, and reverses the NADH inhibition of hepatic gluconeogenesis while also inhibiting the transformation of chloroethylamine into Chloroacetaldehyde, and also inhibits multiple amine oxidase activities, preventing the formation of Chloroacetaldehyde.20

Hence it has prophylactic and therapeutic role in ifosfamide - induced encephalopathy.21

METHYLENE BLUE AS DYE AND STAIN
Methylene blue infusion was found as a safe and effective method of localizing abnormal parathyroid glands.22

Methylene blue has also been used for intraoperative endoscopic marking of intestinal lumen for location of lesions.23

Methylene blue was also found as an effective and cheap alternative to isosulfan blue dye for sentinel lymph node localization in pt with breast cancer.24

Methylene blue also has been used in diagnostic microbiology as a stain. It is an inexpensive and rapid method for detection of H.pylori.25

NEUTRALIZATION OF HEPARIN
Methylene blue effectively neutralizes heparin especially in pts with protamine allergy. However work still needs to be done to determine the safety of the drug at the higher doses necessary to neutralize heparin levels achieved in bypass patients.26

METHYLENE BLUE AND PRIAPISM
Methylene blue has been used to treat high flow priapism by intra-cavernous injection which is known to antagonize endothelial derived relaxation factor.27

METHYLENE BLUE AND ALZHEIMER’S DISEASE
The relationship between Methylene blue and Alzheimer’s disease has recently attracted increasing scientific attention. It has been shown to attenuate the formations of amyloid plaques and neurofibrillary tangles and partial repair of impairments in mitochondrial function and cellular metabolism.28

METHYLENE BLUE COMBINED WITH LIGHT
Photodynamic therapy using the light activated anti-microbial agent, Methylene blue kills methicillin resistant staphylococcus aureus (MRSA) in superficial and deep excisional wounds.29 Methylene blue in combination with light also inactivates viral nucleic acid of hepatitis-C and human immunodeficiency virus (HIV-1) and treats cases of resistant plaque psoriasis.30,31

ADVERSE EFFECTS
Methylene blue is a safe drug when used in therapeutic
doses (<2mg/kg). But it can cause toxicity in high doses. The features of toxicity being cardiac arrhythmias, coronary vasoconstriction, decreased cardiac output, renal blood flow and mesenteric blood flow; increased pulmonary vascular pressure & pulmonary vascular resistance and gas exchange deterioration. It also turns urine greenish blue and bluish discoloration of skin and mucosa which is self limiting.4, 7

Due to its tissue reactive properties, a case of skin and fat necrosis followed by a dry gangrene of the skin in a female patient with breast cancer who underwent sentinel lymph node biopsy localization using peri-tumoral injection of Methylene blue dye has been reported.32

It can also cause hemolytic anemia characterized by Heinz body formation especially in pts with severe renal insufficiency and glucose-6-phosphate dehydrogenase (G6PD) deficiency.18

Neonates are particularly prone to adverse effects of Methylene blue. It causes hyperbiliuribinemia, meth-Hemoglobin formation, hemolytic anemia, respiratory distress, pulmonary edema, photo toxicity and bluish discoloration of tracheal secretions and urine.33, 34, 35, 36, 37, 38, 39, 40, 41

Methylene Blue also interferes with the pulse oximeter’s light emission resulting in falsely depressed oxygen saturation reading.18

Methylene blue due to its monoamine oxidase (MAO) inhibiting property may precipitate potentially fatal serotonin toxicity at doses >5mg/kg 42 and rarely can cause severe anaphylactic shock.43

CONTRAINDICATIONS
Methylene blue is contraindicated in patients who have developed hypersensitivity reactions to it and in severe renal insufficiency. It is relatively contraindicated in G6PD deficient patients as it can cause severe hemolysis and also in patients with Heinz body anemia.18, 43

DRUG INTERACTIONS
Methylene blue is a MAO inhibitor and therefore can interact with selective serotonin reuptake inhibitor (SSRI) and MAO inhibitors to cause serious serotonin toxicity.42, 43

It also interacts with dapsone and forms hydroxylamine which oxidizes hemoglobin causing hemolysis.18

CONCLUSIONS
Methylene Blue was till now known mainly as a dye but is now entering into the field of cardiac surgery and critical care as a very important therapeutic agent with diverse applications. The evidence for its use in methemoglobinemia is well established but that for its use in vasoplegia, septic shock, hepatopulmonary syndrome, malaria, ifosfamide neurotoxicity etc is limited but promising and commands more research.

REFERENCES
1. Bosoy, Dimitry, Axelband, et al. Utilization of methylene blue in the setting of hypotension associated with concurrent renal and hepatic failure: a concise review. OPUS 12 Scientist 2008; 2: 21-9.
2. Peter schenk, Christian Madl, Shahraz Rezaie-Majd, Stephen Lehr, Christian Muller. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133: 701-6.
3. Preiser, Jean-Charles, Lejeune, et al. Methylene blue administration in septic shock: A Clinical Trial. Critical Care Medicine 1995; 23: 259-64.
4. Ertugrul Ozal, Erkan Kuralay, Vedat Yildirim, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005; 79: 1615-9.
5. Armand Mekontso-Dessap, Remi Houel, Celine Soustelle, Matthias Kirsch, Dominique Thebert, Daniel Y.Loisance. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001; 71: 1428-32.
6. Tuman KJ, McCarthy RJ, O’Connor CJ, Holm WE, Ivankovich AD. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg 1995; 80: 473-9.
7. Reiner G. Leyh, Theo Kofidis, Martin Struber, et al. Methylene Blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg 2003; 125: 1426-31.
8. Ricardo L. Levin, Marcela A. Degrange, Gustavo F. Bruno, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77: 496-9.
9. B. Gachot, J.P. Bedos, B. Veber, M. Wolff, B. Regnier. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Medicine 1995; 21: 1027-31.
10. M.Grayling, C. D.Deakin. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003; 125: 426-7.
11. T. Kofidis, M. Struber, M. Wilhelmi, et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thoracic Cardiovasc Surg 2001; 122: 823-4.
12. Evora PRB, Riberio PJF, Andrade JCS. Methylene blue
administration in SIRS after cardiac operations. Ann Thorac Surg 1997; 63; 12-3.
13. Moritoki Egi, Rinaldo Bellomo, Christoph Langenberg, et al. selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: A systematic literature review. Ann Thorac Surg 2007; 83; 715-23.
14. Edmund S. H. Kwok, Daniel Howes. Use of methylene blue in sepsis: A Systematic Review. Journal of Intensive Care Medicine 2006; 21: 359-63.
15. Peter E Meissner, Germain Mandi, Boubacar Coulibaly, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malaria Journal 2006; 5; 84.
16. Schirmer R.H, Coulibaly B, Stich A, et al. Methylene blue as an antimalarial agent. Redox rep 2003; 8: 272-5.
17. Marianne Boylston, Deborah Beer. Methemoglobinemia: A Case Study. Critical Care Nurse 2002; 22: 50-5.
18. Clifton, Jack II, Leikin, Jerrold. Methylene blue. American Journal of Therapeutics 2003; 10: 289-91.
19. Wondrak GT. NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med 2007; 43: 178-90.
20. Alici-Evcimen Y, Breitbart WS. Ifosfamide neuropsychiatric toxicity in patients with cancer. Psychooncology 2007; 16: 956-60.
21. J Pelgrims, F De Vos, J Van den Brande, D Schrijvers, Prové, JB Vermorken. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. British Journal of Cancer 2000; 82: 291-4.
22. Donald L. Gordan, Mohan C. Airan, William Thomas, Leon H. Seidman. Parathyroid identification by methylene blue infusion. British Journal of Surgery 2005; 82: 747-9.
23. R.I. Beretvas, J. Ponsky. Endoscopic marking: an adjunct to laparoscopic gastrointestinal surgery. Surgical Endoscopy 2001; 15: 1202-3.
24. Simmons RM, Smith SM, Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Breast J 2001; 7: 181-3.
25. V. Misra, SP Misra, M. Dwivedi, SC Gupta. The Loeffler's methylene blue stain: An inexpensive and rapid method for detection of helicobacter pylori. Journal of Gastroenterology and Hepatology 2008; 9: 512-3.
26. Sloand EM, Kessler CM, McIntosh CL, Klein HG. Methylene blue for neutralization of heparin. Thromb Res 1989; 54: 677-86.
27. Steers WD, Selby JB. Use of methylene blue and selective embolization of the pudendal artery for high flow priapism refractory to medical and surgical treatments. J Urol 1991; 146: 1361-3.
28. Murat Oz, Dietrich E. Lorke, George A. Petroianu. Methylene blue and Alzheimer’s disease. Biochemical pharmacology 2009; 78: 927-32.
29. Parjam S Zolfaghari, Samantha Packer, Mervyn Singer, et al. In vivo killing of Staphylococcus aureus using light-activated antimicrobial agent. BMC Microbiology 2009; 9: 27.
30. Muller-Breitkreutz, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol 1998; 56: 239-45.
31. Salah M, Samy N, Fadel M. Methylene blue mediated photodynamic therapy for resistant plaque psoriasis. J Drugs Dermatol 2009; 8: 42-9.
32. M Salhab, W Al sarabbi, K Mokbel. Skin and fat necrosis of the breast following methylene blue dye injection for sentinel node biopsy in a patient with breast cancer. Int Semin Surg Oncol. 2005; 2: 26.
33. Cowett RM, Hakanson DO, Kocon RW, Oh W. Untoward neonatal effect of intraamniotic administration of methylene blue. Obstet Gynecol 1976; 48:74-5.
34. Crooks J. Haemolytic jaundice in a neonate after intraamniotic injection of methylene blue. Arch Dis Child 1982; 57: 872-3.
35. Fish WH, Chazan EM. Toxic effects of methylene blue on the fetus. Am J Dis Child 1992; 146: 1412-3.
36. Plunkett GD. Neonatal complications. Obstet Gynecol 1973; 41: 476-7.
37. Porat R, Gilbert S, Magliner D. Methylene blue-induced phototoxicity: An unrecognized complication. Pediatrics 1996; 97: 717-21.
38. Serota FT, Bernbaum JC, Schwartz E. The methylene-blue baby. Lancet 1979; 2: 1142-3.
39. Spahr RC, Salsbury DJ, Krissberg A, Prin W. Intraamniotic injection of methylene blue leading to methemoglobinemia in one of twins. Int J Gynaecol Obstet 1980; 17: 477-8.
40. Troche BI. The methylene blue baby. N Engl J Med 1989; 320: 1756-7.
41. Vincer MJ, Allen AC, Evans JR, Nwaasei C, Stinson DA. Methylene-blue-induced hemolytic anemia in a neonate. Can Med Assoc J 1987; 136: 503-4.
42. Gillman P K. Methylene blue implicated in potentially fatal serotonin toxicity. Anaesthesia 2006; 61: 1013-4.
43. Pascale Dewachter, Claudie Moutan-Faivre, Philippe Trechot, Jean-Claude Lleu, Paul Michel Mertes. Severe anaphylactic shock with methylene blue instillation. Anesth Analg 2005; 101: 149-50.